Canabo Medical (TSXV:CMM) has announced it has opened its 15th clinic in London, Ontario. As quoted in the press release: Canabo is also pleased to announce that Dr. Neil Smith, Executive Chairman will be presenting results from the Company’s Observational Study at the Canadian Consortium for the Investigation of Cannabinoids (CCIC) “Cannabinoids in Clinical Practice” …

Canabo Medical (TSXV:CMM) has announced it has opened its 15th clinic in London, Ontario.
As quoted in the press release:

Canabo is also pleased to announce that Dr. Neil Smith, Executive Chairman will be presenting results from the Company’s Observational Study at the Canadian Consortium for the Investigation of Cannabinoids (CCIC) “Cannabinoids in Clinical Practice” event April 6-7, 2017 in Toronto. The research to be presented will focus on observations of benzodiazepine use among Canabo patients. The Company currently tracks over 1,500 patients who started medical cannabinoids while on benzodiazepines.
Dr. Smith stated, “We consider the release of this first research report a milestone not just for Canabo but for the medical cannabis industry as a whole. We anticipate that the results of our first study will be significant within the medical community as a large number of patients under our treatments completely eliminated benzodiazepines from their medication regime.”

Click here to read the full press release.

Source: www.canabocorp.com

canabo medical cannabinoids london medical cannabis industry ontario patients toronto tsxv:cmm Cannabis Investing